Application of bone marrow mesenchymal stem cells in hematopoietic stem cell transplantation for sensitized and non-sensitized BALB/c mice
10.3969/j.issn.2095-4344.2015.32.024
- VernacularTitle:骨髓间充质干细胞在致敏与非致敏BALB/c小鼠造血干细胞移植中的应用
- Author:
Xiaowei GUO
;
Chenxia GUAN
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2015;(32):5215-5219
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Hematopoietic stem cel transplantation has therapeutic effects on many diseases, but its application has some limitations, such as cel harvesting and age-limited number of cels.
OBJECTIVE: To investigate the application value of bone marrow mesenchymal stem cels in hematopoietic stem cel transplantation for sensitized and non-sensitized BALB/c mice.
METHODS: Bone marrow cels derived from BALB/c mice were isolated and culturedin vitro to harvest mesenchymal stem cels using adherent method. The cel surface markers were detected by flow cytometry. A murine model of sensitization was established by transfusion of alogeneic spleen cels. Mesenchymal stem cels labeled with green fluorescent dye were transplanted into non-sensitized and sensitized recipient mice, and the homing of mesenchymal stem cels in vivowas monitored at different time points post transplantation. Additionaly, under irradiation pretreatment, sensitized BALB/c mice under irradiation were subjected to combined transplantation of alogeneic bone marrow cels and syngeneic mesenchymal stem cels. Survival rate of BALB/c mice was monitored daily.
RESULTS AND CONCLUSION: At 48 hours after transplantation, mesenchymal stem cels in sensitized and non-sensitized recipients were homing to the spleen and bone marrow, respectively. In the experiment of hematopoietic stem cel transplantation, the sensitized recipients died at 12-15 days after combined transplantation, with a median of 14 days; however, the sensitized recipients only undergoing alogeneic bone marrow cel transplantation had a survival median of 13 days. These findings indicate that the transplanted mesenchymal stem cels in sensitized recipients are mainly homing to the spleen and bone marrow, but the combination transplantation cannot enhance the transplantation of alogeneic hematopoietic stem/progenitor cels in sensitized recipients.
